The Online Investor
Scopus BioPharma Inc (SCPS)

Scopus BioPharma is a clinical-stage biopharmaceutical company developing therapeutics targeting diseases. Co. has launched its Duet BioTherapeutics, Inc., which integrates the management and clinical development of immunotherapy (the Duet Platform). Co. has several licenses, a research agreement and a clinical research support agreement relating to the Duet Platform with City of Hope. The Duet Platform is comprised of complementary bifunctional oligonucleotides that each consist of a toll-like receptor 9 agonist linked with a signal transducer and activator of transcription 3 inhibitor: RNA silencing, CpG-STAT3siRNA; antisense, CpG-STAT3ASO; and DNA-binding inhibitor, CpG-STAT3decoy.
Company Name: 
Scopus BioPharma Inc
Website: 
www.scopusbiopharma.com
Sector: 
Biotechnology
Quotes delayed 20 minutes

Email EnvelopeFree SCPS Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Scopus BioPharma Inc (SCPS) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.